Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration. - Test2 - elhamkhani - TriplyDB

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.

http://www.wikidata.org/entity/Q33701979

about

Caspase-11 non-canonical inflammasome: a critical sensor of intracellular lipopolysaccharide in macrophage-mediated inflammatory responses.Therapeutic Antibodies against Intracellular Tumor Antigens Production of recombinant human procollagen type I C-terminal propeptide and establishment of a sandwich ELISA for quantification.Role of inflammasomes in inflammatory autoimmune rheumatic diseases.Recent advances in the biology and therapy of medullary thyroid carcinoma.KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment Targeted Intracellular Delivery of Antibodies: The State of the Art

P2860

Q39427816-AC9CB9CD-8B69-48B3-A8DE-4A81AD4018C3 Q41462883-1E6FFDEF-FC2E-41AE-80D8-4104B50D45B9 Q46436623-C7515038-D6D2-42CA-8671-17F137E2B33E Q47199815-C4AF39E6-6BC9-4296-B5EB-B561A5508BAD Q48246978-95FD3718-93C8-4F0E-B149-FD2A7C3A9FE1 Q57072901-16478CE1-83E2-4A4F-A4B8-474B849ED911 Q58046152-CC78F992-D63C-4119-BA37-1FF08C5A7D48 Q58566968-FD2CCF7F-C39C-4906-A024-3113FB17A93F

P2860

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.

http://www.wikidata.org/entity/Q33701979

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Antibody targeting intracellul ...... after systemic administration.

@ast

Antibody targeting intracellul ...... after systemic administration.

@en

type

label

Antibody targeting intracellul ...... after systemic administration.

@ast

Antibody targeting intracellul ...... after systemic administration.

@en

prefLabel

Antibody targeting intracellul ...... after systemic administration.

@ast

Antibody targeting intracellul ...... after systemic administration.

@en

P1433

Q33701979-46C126F4-F14D-4177-B841-39AFDDA4D457

P1476

Q33701979-29864BF5-45BD-4998-8ADD-9B8849A740FF

P2093

Q33701979-18FDD363-D391-4752-A68F-1B79AD91D2E6

Q33701979-19AD3E18-A413-4AD7-98F3-057B1A32997F

Q33701979-70C58C00-4DBD-4438-A4A5-269AA69D3DF4

Q33701979-A3FB3F16-7491-4B5C-8927-7DBE061D96C3

Q33701979-CD7D3289-E4B2-4D24-BBE8-3DD380EBC885

Q33701979-D5E1990D-72C3-4E79-B287-3AC780DAAB59

Q33701979-E89961F9-F408-428C-8677-417260458180

P2860

Q33701979-09BC1EF6-BBF0-4033-828C-0103B04989FB

Q33701979-112A2D73-02AD-4F63-9DB2-402BF3DE310A

Q33701979-12DAE4FB-30A3-4611-9E5A-FEF692C66C77

Q33701979-1A3E47F2-5F95-48D1-9E6E-540289A6E900

Q33701979-2B95BC01-F35A-428E-915A-B0E6F5BE99E8

Q33701979-2BC5B282-C3AA-49D6-9D50-BBC5F0970FE9

Q33701979-332DEF56-37CE-4FD0-9B7D-92D190B71DD5

Q33701979-37EB54B6-BC03-451B-9D92-807D730A7842

Q33701979-38435955-5D5B-40E0-8298-C5208CADBAA4

Q33701979-3A5EB069-3CDE-481C-8E78-C96999AD486A

P2888

Q33701979-49B71ED9-6181-4228-85B8-C55E85730C79

P304

Q33701979-BEACF99E-692C-4265-A469-CC13AB79C388

P31

Q33701979-651D9A8F-D5DE-48C7-889F-2B1D97B38FAF

P356

Q33701979-BC71C78A-0612-4F66-B5B4-50EF9ED0896B

P407

Q33701979-CFB5F5E9-ED5B-4980-AD79-0098E0440082

P478

Q33701979-53A7CB0B-6A00-4849-87BA-820AD0477D11

P50

Q33701979-21A3F72B-50B4-435F-BDB6-1151F9BEA248

P577

Q33701979-41249347-9492-431B-B8DB-77D3F681B2DE

P6179

Q33701979-AEFC32CA-A6C1-42D6-9D5C-C0E79033A930

P698

Q33701979-9E8367A0-2DD2-44DF-B2FC-3893DBED1A2B

P932

Q33701979-AAFB74EF-CE81-4C51-86C5-430C9D402D89

P356

P1433

Nature Communications

P1476

Antibody targeting intracellul ...... after systemic administration

@en

P2093

Dong-Ki Choi

http://www.w3.org/2001/XMLSchema#string

Jeomil Bae

http://www.w3.org/2001/XMLSchema#string

Ji-Sun Kim

http://www.w3.org/2001/XMLSchema#string

Keunok Jung

http://www.w3.org/2001/XMLSchema#string

Ki-Hoon Song

http://www.w3.org/2001/XMLSchema#string

Seong-Wook Park

http://www.w3.org/2001/XMLSchema#string

Seung-Min Shin

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma

Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS

In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction

Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins

Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations

P2888

P304

15090

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS15090

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085378074

http://www.w3.org/2001/XMLSchema#string

P698

28489072

http://www.w3.org/2001/XMLSchema#string

P932

5436137

http://www.w3.org/2001/XMLSchema#string